Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
FROM:
Jerry McGinty, Director, Legislative Budget Board
IN RE:
SB426 by Paxton (Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.), As Introduced
No significant fiscal implication to the State is anticipated.
Based on the analysis of the Texas Medical Board and the Health and Human Services Commission, duties and responsibilities associated with implementing with bill could be accomplished by utilizing existing resources.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies:
503 Texas Medical Board, 529 Health and Human Services Commission